Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib in Breast Cancer Patients With Poor Response to Neoadjuvant Trastuzumab Combined With Pertuzumab
NCT04255056Phase 2Unknown
- Sponsor
- Sun Yat-sen University
- Start
- Feb 2020
- Primary completion
- Feb 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Sun Yat-sen University. Primary endpoint: Total Pathological Complete Remission at 1 year. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04255056.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04255056.